The Healthcare Compliance
Packaging Council

Tuesday, March 12, 2013

7:30 - 8:30 AM

Continental Breakfast

8:30 AM

Opening Remarks

8:40-9:20

Opening Keynote presentation -

Efforts to Advance Medication Adherence, Savings and Outcomes In a Deficit Reduction Environment

Joel White, Health Coverage Executive Director, Council for Affordable Healthcare

The lame duck session of the 112th Congress sets the stage for a year of hard bargaining on measures to trim a projected $10 trillion in budget deficits over the next decade alone. This intense focus on fiscal retrenchment will ignite legislative interest in a new round of health reforms in 2013 because health programs account for three-quarters of non-interest spending growth in the Congressional Budget Office's 10-year budget baseline. Put simply, reducing the deficit means lowering rising health costs. Poor medication adherence, or non-adherence, affects patient health by reducing the ability to effectively manage and control chronic diseases. Patients with adherence issues are more likely to experience preventable disease progression, increased hospitalizations, doctor and emergency room visits and other problems arising from poor health. This can significantly increase costs.

As a result of Congress and the Administration's efforts to lower health spending, there may be opportunities to advance medication adherence in Medicare, Medicaid and in private markets. Mr. White will explore current and planned efforts to advance medication adherence policy as Congress considers the next round of deficit reduction measures.

9:20 - 10:10

Estimated Annual Pharmaceutical Revenue Loss Due to Medication Non-Adherence

Thomas Forissier, Principal, Capgemini Consulting's Life Sciences Sector and co- lead of the Life Sciences Customer Experience Practice, Capgemini Consulting & Katrina Firlik, MD. Chief Medical Officer, HealthPrize Technologies

Medication non-adherence is one of the most serious problems in healthcare, posing a heavy financial impact on all constituencies. On the cost side, the New England Healthcare Institute estimated that medication non-adherence is responsible for $290 billion in "otherwise avoidable medical spending" in the US alone each year. On the pharmaceutical revenue side, however, the impact of medication non- adherence had yet to be accurately quantified. The market assumption relied upon to date, and quoted extensively, has been $30 billion globally, which we felt was a gross underestimate. This presentation will cover the most accurate estimate of pharmaceutical revenue loss due to medication non-adherence and how increasing adherence rates by only 10 percentage points would translate into a $41 billion pharmaceutical revenue opportunity in the US ($124 billion globally), accompanied by improved health outcomes and decreased healthcare spending.

10:10 - 11:00

Improving Medication Adherence and Reducing Readmissions

Thomas E. Hubbard
Vice President for Policy Research, NEHI

High hospital readmissions rates are seen as a key contributor to rising health care costs. New government payment reforms are tackling the problem by penalizing hospitals for such readmissions, and innovative providers are responding with better planning and follow-up care after a patient is discharged. Medication management by health care teams is at the heart of this effort. This presentation will review these models of discharge planning and follow-up care that not only reduce readmissions but highlight the valuable role of medication management in improving patient outcomes and the need for improved medication adherence throughout the health care system.

11:00 - 11:20

Networking, Exhibits & Refreshment Break

- graciously sponsored by

11:20 - 12:10

The A³ Project: Developing a Collaborative Adherence Action Agenda

Ray Bullman, Executive Vice President
National Council on Patient Information and Education (NCPIE)

Representatives from over two dozen diverse organizations have come together to provide input into the development of a comprehensive, collaborative, multi-stakeholder Adherence Action Agenda (The A3 project), addressing four key focus areas: 1) Chronic Conditions and Co-Morbidities; 2) Critical Macro Factors; 3) Patient-related Factors, and 4) Healthcare Professional Factors. This session will provide an update on the formulation of the strategic project framework, implementation schedule, identification of lead monitoring organizations and next steps.

Support for the initial phase of the multi-year A3 Project provided by Merck.

12:10 - 1:10

Luncheon

- graciously sponsored by

1:15 - 1:45

HCPC Compliance Package of the Year Awards Ceremony & Presentation of Winning Packages

1:45 - 2:25

Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence

Michael Eaddy, PharmD, PhD, Vice President, Xcenda and Justin Schroeder, Senior Director, Marketing & Development Services, AndersonBrecon

Patient medication adherence poses significant concerns to health care professionals, particularly for those patients who have a chronic disease that requires long term, consistent medication, like hypertension. The use of unit dose calendarized formats in one tool in addressing the underlying causes of poor adherence. In this presentation, Michael Eaddy and Justin Anderson will present the findings of the recently published Xcenda study conducted to highlight successful patient adherence improvements using the Novartis Pharmaceuticals' DiovanHCT® antihypertensive therapy in a 30 day reminder package distributed by a major retail pharmacy.

2:25 - 3:05

Improving Patient Adherence in Clinical Trials

Kathy Zonca, Patient Adherence Consultant, C3i, Inc.

Patient adherence has been described as the "other" drug problem in routine clinical practice. But is it an issue in clinical trials where one expects the patients to be more highly motivated to adhere? In this session, we will explore reasons that adherence might be lower than desired in trials and how non-adherence can impact clinical research results. We will also look at other closely related areas of concern that can impact the integrity of trial data. Finally, we will offer some suggestions for ways to improve patient adherence in the clinical trial setting.

3:05 - 3:25

Networking, Exhibits & Refreshment Break

- graciously sponsored by

3:25 - 4:05

Delivering Breakthrough Medicine with Device Innovation

Mark Novara, Worldwide Strategic Marketing Director, BD Medical-Pharmaceutical Systems

This talk will cover three main objectives: key design principles to device innovation; best practices to execute these design principles; and case study on the BD™ Microinfusor patch injector (novel, high volume delivery solution).

4:05 - 4:50

Industry Perspective Panel - join our industry experts as they collaborate on the effective methods of improving patient adherence based on their knowledge and experience in the field

Moderator:
David Vaczek, Senior Editor, Pharmaceutical & Medical Packaging News

Panelists:
Michael Eaddy, PharmD, PhD, Vice President, Xcenda
Katrina Firlik, MD. Chief Medical Officer, HealthPrize Technologie
Thomas Forissier, Principal, Capgemini Consulting's Life Sciences Sector and co-lead of the Life Sciences Customer
Experience Practice, Capgemini Consulting
Thomas E. Hubbard, Vice President for Policy Research, NEHI
Kathy Zonca, Patient Adherence Consultant, C3i, Inc.

Closing Remarks

Thank you to our additional sponsors: